Greater precision than genomics only,* providing a clearer view of therapy response2
Better stratify patients with improved PFS compared with genomic variant-based methods1
*3x higher precision estimated in comparison to response tracking with 3 somatic mutations for a representative sample at 0.1% tumor fraction and typical input amount.
CH, clonal hematopoiesis; PFS, progression-free survival.
Guardant Infinity is for Research Use Only. Not for use in diagnostic procedures.
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
QUANTIFY CANCER
Guardant Infinity’s methylation-based monitoring delivers accurate ctDNA detection while overcoming challenges of genomic variant-based methods.¹
New data demonstrate Guardant Infinity’s high precision in monitoring for early and long-term response to therapy and disease progression
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma InfinityAI for BioPharma
20% increase in quantifiable rate compared with genomic-only approaches after excluding variants confirmed as CH1